296 related articles for article (PubMed ID: 26469696)
1. Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.
Hendrickx S; Leemans A; Mondelaers A; Rijal S; Khanal B; Dujardin JC; Delputte P; Cos P; Maes L
PLoS One; 2015; 10(10):e0140139. PubMed ID: 26469696
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
[TBL] [Abstract][Full Text] [Related]
3. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
Hendrickx S; Inocêncio da Luz RA; Bhandari V; Kuypers K; Shaw CD; Lonchamp J; Salotra P; Carter K; Sundar S; Rijal S; Dujardin JC; Cos P; Maes L
PLoS Negl Trop Dis; 2012; 6(5):e1664. PubMed ID: 22666513
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains.
Shaw CD; Imamura H; Downing T; Blackburn G; Westrop GD; Cotton JA; Berriman M; Sanders M; Rijal S; Coombs GH; Dujardin JC; Carter KC
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658971
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
[TBL] [Abstract][Full Text] [Related]
6. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes.
Maarouf M; Adeline MT; Solignac M; Vautrin D; Robert-Gero M
Parasite; 1998 Jun; 5(2):167-73. PubMed ID: 9754313
[TBL] [Abstract][Full Text] [Related]
10. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.
Kulshrestha A; Singh R; Kumar D; Negi NS; Salotra P
Antimicrob Agents Chemother; 2011 Jun; 55(6):2916-21. PubMed ID: 21464251
[TBL] [Abstract][Full Text] [Related]
11. A Novel Spirooxindole Derivative Inhibits the Growth of Leishmania donovani Parasites both In Vitro and In Vivo by Targeting Type IB Topoisomerase.
Saha S; Acharya C; Pal U; Chowdhury SR; Sarkar K; Maiti NC; Jaisankar P; Majumder HK
Antimicrob Agents Chemother; 2016 Oct; 60(10):6281-93. PubMed ID: 27503653
[TBL] [Abstract][Full Text] [Related]
12. Leishmania donovani develops resistance to drug combinations.
García-Hernández R; Manzano JI; Castanys S; Gamarro F
PLoS Negl Trop Dis; 2012; 6(12):e1974. PubMed ID: 23285310
[TBL] [Abstract][Full Text] [Related]
13. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
Seifert K; Munday J; Syeda T; Croft SL
J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Transplasma Membrane Electron Transport Chain in Wild and Drug-Resistant Leishmania donovani Promastigote and Amastigote.
Debnath D; Hossain MA; Das M; Kabir A; Ibrahim M; Amin MN; Chowdhury A; Pervin R
Acta Parasitol; 2019 Dec; 64(4):710-719. PubMed ID: 30941668
[TBL] [Abstract][Full Text] [Related]
15. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani.
Chawla B; Jhingran A; Panigrahi A; Stuart KD; Madhubala R
PLoS One; 2011; 6(10):e26660. PubMed ID: 22046323
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
17. The sensitivity of Leishmania species to aminosidine.
Neal RA; Allen S; McCoy N; Olliaro P; Croft SL
J Antimicrob Chemother; 1995 May; 35(5):577-84. PubMed ID: 7592170
[TBL] [Abstract][Full Text] [Related]
18. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
20. Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum.
Jesús Corral-Caridad M; Moreno I; Toraño A; Domínguez M; Alunda JM
Exp Parasitol; 2012 Dec; 132(4):475-82. PubMed ID: 22995646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
